காயங்கள் காடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from காயங்கள் காடு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In காயங்கள் காடு Today - Breaking & Trending Today
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease Home / Top News / Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease Efficacy analysis demonstrates COVAXIN™ to be 93.4% protective against severe symptomatic COVID-19 Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant Adverse events reported were similar to placebo, with 12.4% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events MALVERN, Pa., and HYDERABAD, India, July 02, 2021 (GLOBE NEWSWIRE) ....
In a move that will delay rollout of indigenous Covid-19 vaccine Covaxin in the US market, Bharat Biotech’s US partner Ocugen has dropped plans of app ....
India News: HYDERABAD: Bharat Biotech’s US partner, Ocugen, has dropped plans to apply for emergency-use authorisation (EUA) for Covaxin in the US and will instea. ....
The US Food and Drug administration has denied approval for emergency use of Covaxin, developed by Hyderabad-based Bharat Biotech, and has asked for additional data, biopharmaceutical Ocugen, the US partner of the Indian vaccine maker has . ....